Afinitor (everolimus, RAD001)
Published: Dec 26, 2009 4:57 pm
| Brand Name: | Afinitor |
| Generic Name: | everolimus |
| Code Name: | RAD001 |
| Company: | Novartis |
| FDA Clinical Phase: | 1/2 |
Description:
Afinitor was approved by the FDA in March 2009 for the treatment of advanced renal cell carcinoma, but it is currently also being studied in multiple myeloma. It works by inhibiting an enzyme called mammalian target of rapamycin (mTOR). The enzyme mTOR has a role in cell growth and is associated with tumor progression. Afinitor blocks this enzyme’s activity, reducing both tumor cell growth and growth of blood vessels (angiogenesis) connected to tumor cells. Clinical trials studying the effects of Afinitor in relapsed, recurrent, and refractory multiple myeloma are underway.
Clinical Trials:
For a list of clinical trials studying Afinitor for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for Afinitor: http://www.afinitor.com.
Related Articles:
- Getting To Know: Tiragolumab
- Getting To Know: TNB-383B
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Lather, Rinse, Repeat: Will It Work With BCMA-Targeted Therapies For Multiple Myeloma?
